The estimated Net Worth of Suresh K. Durgam is at least $5.51 million dollars as of 7 March 2024. Dr Durgam owns over 10,162 units of Intra-Cellular Therapies Inc stock worth over $1,479,680 and over the last 4 years he sold ITCI stock worth over $3,302,822. In addition, he makes $730,360 as Sr. VP & Chief Medical Officer at Intra-Cellular Therapies Inc.
Sign up
Dr D ITCI stock SEC Form 4 insiders trading
Dr has made over 17 trades of the Intra-Cellular Therapies Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 10,162 units of ITCI stock worth $672,826 on 7 March 2024.
The largest trade he's ever made was exercising 62,282 units of Intra-Cellular Therapies Inc stock on 2 January 2024 worth over $1,237,543. On average, Dr trades about 10,067 units every 55 days since 2021. As of 7 March 2024 he still owns at least 19,803 units of Intra-Cellular Therapies Inc stock.
You can see the complete history of Dr Durgam stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Suresh K. Durgam M.D. biography
Dr. Suresh K. Durgam M.D. is the Sr. VP & Chief Medical Officer at Intra-Cellular Therapies Inc.
What is the salary of Dr D?
As the Sr. VP & Chief Medical Officer of Intra-Cellular Therapies Inc, the total compensation of Dr D at Intra-Cellular Therapies Inc is $730,360. There are 9 executives at Intra-Cellular Therapies Inc getting paid more, with Sharon Mates having the highest compensation of $4,724,560.
How old is Dr D?
Dr D is 52, he's been the Sr. VP & Chief Medical Officer of Intra-Cellular Therapies Inc since . There are 13 older and 3 younger executives at Intra-Cellular Therapies Inc. The oldest executive at Intra-Cellular Therapies Inc is Richard Lerner, 81, who is the Independent Director.
What's Dr D's mailing address?
Suresh's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK, NY, 10016.
Insiders trading at Intra-Cellular Therapies Inc
Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus et Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.
What does Intra-Cellular Therapies Inc do?
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
What does Intra-Cellular Therapies Inc's logo look like?
Complete history of Dr Durgam stock trades at Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc executives and stock owners
Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:
-
Sharon Mates,
Chairman of the Board, President, Chief Executive Officer -
Mark Neumann,
Executive Vice President, Chief Commercial Officer -
Michael Halstead,
Executive Vice President, General Counsel and Secretary -
Lawrence Hineline,
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary -
Robert Davis,
Senior Vice President and Chief Scientific Officer -
Kimberly Vanover,
Senior Vice President, Early Stage Clinical Development and Translational Medicines -
Dr. Sharon Mates,
Co-Founder, Chairman, CEO & Pres -
Mark Neumann,
EVP & Chief Commercial Officer -
Michael I. Halstead J.D.,
Exec. VP, Gen. Counsel & Sec. -
Dr. Suresh K. Durgam M.D.,
Sr. VP & Chief Medical Officer -
Lawrence J. Hineline CPA, CPA,
Sr. VP of Fin., CFO, Treasurer & Assistant Sec. -
Robert Van Nostrand,
Lead Independent Director -
Joel Marcus,
Independent Director -
Christopher Alafi,
Independent Director -
Rory Riggs,
Independent Director -
Richard Lerner,
Independent Director -
Michael Olchaskey,
Senior Vice President, Head of Regulatory Affairs -
Suresh Durgam,
Chief Medical Officer -
John Bardi,
Senior Vice President - Market Access, Policy and Government Affairs -
Karen Patruno Sheehy Esq.,
Sr. VP & Chief Compliance Officer -
Juan Fernando Sanchez,
VP of Corp. Communications & Investor Relations -
Dr. Robert E. Davis Ph.D.,
Sr. VP & Chief Scientific Officer -
Moshe Alafi,
10% owner -
Capital Co Llc Alafi,
10% owner -
Juan F. Sanchez,
VP, Corp. Communications & IR -
Allen A. Fienberg,
VP of Business Development -
Lawrence P. Wennogle,
Vice President, Drug Discovery -
Michael Rawlins,
Director -
Eduardo Rene Salas,
-
Sanjeev Narula,
Executive Vice President & CFO